NasdaqGM:TVTXBiotechs
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Pullback
Recent Stock Performance and Business Context
Travere Therapeutics (TVTX) has drawn investor attention after recent trading that leaves the shares about 8.5% lower over the past month and roughly 27.7% lower over the past 3 months.
The company focuses on therapies for rare kidney and metabolic diseases, generates US$490.7m in revenue, and currently reports a net loss of US$50.3m, which keeps profitability and funding on many investors’ radar.
See our latest analysis for Travere...